Zimmer Biomet Ownership
| ZBH Stock | USD 110.64 0.32 0.29% |
Shares in Circulation | First Issued 2000-03-31 | Previous Quarter 206.4 M | Current Value 203 M | Avarage Shares Outstanding 207 M | Quarterly Volatility 22.1 M |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Zimmer |
Zimmer Stock Ownership Analysis
About 93.0% of the company outstanding shares are owned by institutional investors. The company has Price to Book (P/B) ratio of 1.79. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zimmer Biomet Holdings has Price/Earnings To Growth (PEG) ratio of 1.45. The entity recorded earning per share (EPS) of 5.24. The firm last dividend was issued on the 30th of September 2024. Zimmer Biomet had 103:100 split on the 1st of March 2022. Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates in the musculoskeletal healthcare business in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana. Zimmer Biomet operates under Medical Devices classification in the United States and is traded on New York Stock Exchange. It employs 19500 people. For more information please call Bryan Hanson at 574 373 3333 or visit https://www.zimmerbiomet.com.Besides selling stocks to institutional investors, Zimmer Biomet also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Zimmer Biomet's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Zimmer Biomet's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Zimmer Biomet Quarterly Liabilities And Stockholders Equity |
|
Zimmer Biomet Insider Trades History
Less than 1% of Zimmer Biomet Holdings are currently held by insiders. Unlike Zimmer Biomet's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Zimmer Biomet's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Zimmer Biomet's insider trades
Zimmer Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Zimmer Biomet is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Zimmer Biomet Holdings backward and forwards among themselves. Zimmer Biomet's institutional investor refers to the entity that pools money to purchase Zimmer Biomet's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Van Eck Associates Corporation | 2024-06-30 | 3.3 M | Victory Capital Management Inc. | 2024-09-30 | 3.2 M | Boston Partners Global Investors, Inc | 2024-09-30 | 2.6 M | Allspring Global Investments Holdings, Llc | 2024-06-30 | 2.6 M | Camber Capital Management Llc | 2024-09-30 | 2.5 M | Goldman Sachs Group Inc | 2024-06-30 | 2.4 M | Norges Bank | 2024-06-30 | 2.2 M | Northern Trust Corp | 2024-09-30 | 2.2 M | Legal & General Group Plc | 2024-06-30 | 2 M | Vanguard Group Inc | 2024-09-30 | 23.3 M | Dodge & Cox | 2024-09-30 | 17.1 M |
Zimmer Biomet Holdings Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zimmer Biomet insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zimmer Biomet's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Zimmer Biomet insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Zimmer Biomet's latest congressional trading
Congressional trading in companies like Zimmer Biomet Holdings, is subject to rigorous scrutiny to prevent conflicts of interest and insider trading. This is governed by multiple SEC regulations which were established to foster transparency and deter members of Congress from leveraging non-public information for personal gain. This oversight helps maintain public trust and ensures that investments in Zimmer Biomet by those in governmental positions are based on the same information available to the general public.
| 2024-11-11 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2024-07-08 | Representative Ro Khanna | Acquired Under $15K | Verify | ||
| 2017-01-04 | Senator John Reed | Acquired Under $15K | Verify |
Zimmer Biomet Outstanding Bonds
Zimmer Biomet issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Zimmer Biomet Holdings uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Zimmer bonds can be classified according to their maturity, which is the date when Zimmer Biomet Holdings has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| ZIGGO BD FIN Corp BondUS98954UAB98 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| ZIMMER BIOMET HLDGS Corp BondUS98956PAG72 | View | |
| ZIMMER BIOMET HLDGS Corp BondUS98956PAF99 | View | |
| US98956PAB85 Corp BondUS98956PAB85 | View | |
| ZIMMER BIOMET HLDGS Corp BondUS98956PAH55 | View | |
| ZBH 26 24 NOV 31 Corp BondUS98956PAV40 | View |
Zimmer Biomet Corporate Filings
| 22nd of November 2024 Certification of the accuracy of the financial statements and disclosures | ViewVerify | |
8K | 20th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
| 13th of November 2024 Other Reports | ViewVerify |
Currently Active Assets on Macroaxis
When determining whether Zimmer Biomet Holdings offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Zimmer Biomet's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Zimmer Biomet Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Zimmer Biomet Holdings Stock:Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zimmer Biomet Holdings. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zimmer Biomet. If investors know Zimmer will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zimmer Biomet listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.597 | Dividend Share 0.96 | Earnings Share 5.24 | Revenue Per Share 37.006 | Quarterly Revenue Growth 0.04 |
The market value of Zimmer Biomet Holdings is measured differently than its book value, which is the value of Zimmer that is recorded on the company's balance sheet. Investors also form their own opinion of Zimmer Biomet's value that differs from its market value or its book value, called intrinsic value, which is Zimmer Biomet's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zimmer Biomet's market value can be influenced by many factors that don't directly affect Zimmer Biomet's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zimmer Biomet's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zimmer Biomet is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zimmer Biomet's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.